Donald Y.M. Leung

Prof. Donald Y.M. Leung


Research Focus & Metrics

Academic Career Length

41Years (1986-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 June 2011 in Immunological Reviews
Verified
Journal Article
Closed access
PDF file
MBMark Boguniewicz
Mark Boguniewicz
DLDonald Y.M. Leung
Donald Y.M. Leung

1 April 2017 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
PBPatrick M. Brunner
Patrick M. Brunner
EGEmma Guttman-Yassky
Emma Guttman-Yassky
DLDonald Y.M. Leung
Donald Y.M. Leung

1 March 2019 in Allergy and Asthma Proceedings
Verified
Journal Article
Closed access
JKJihyun Kim
Jihyun Kim
BKByung Eui Kim
Byung Eui Kim
DLDonald Y.M. Leung
Donald Y.M. Leung
Atopic dermatitis (AD) is the most common chronic inflammatory skin disease. Genetic predisposition, epidermal barrier disruption, and dysregulation of the immune system are some of the critical components of AD. An impaired skin barrier may be the initial step in the development of the atopic march as well as AD, which leads to further skin inflammation and allergic sensitization. Type 2 cytokines as well as interleukin 17 and interleukin 22 contribute to skin barrier dysfunction and the development of AD. New insights into the pathophysiology of AD have focused on epidermal lipid profiles, neuroimmune interactions, and microbial dysbiosis. Newer therapeutic strategies focus on improving skin barrier function and targeting polarized immune pathways found in AD. Further understanding of AD pathophysiology will allow us to achieve a more precision medicine approach to the prevention and the treatment of AD.

1 October 2014 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
DLDonald Y.M. Leung
Donald Y.M. Leung
EGEmma Guttman-Yassky
Emma Guttman-Yassky

1 January 2018 in Allergy, Asthma & Immunology Research
Verified
Journal Article
Open access
PDF file
BKByung Eui Kim
Byung Eui Kim
DLDonald Y.M. Leung
Donald Y.M. Leung
Kim BE, et al. Allergy Asthma Immunol Res. 2018 May;10(3):207-215. https://doi.org/10.4168/aair.2018.10.3.207

15 November 2013 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
EGElena Goleva
Elena Goleva
LJLeisa P. Jackson
Leisa P. Jackson
JHJ. Kirk Harris
J. Kirk Harris
CRCharles Robertson
Charles Robertson
ESE. Rand Sutherland
E. Rand Sutherland
DLDonald Y.M. Leung
Donald Y.M. Leung
Rationale: The role of airway microbiome in corticosteroid response in asthma is unknown. Objectives: To examine airway microbiome composition in patients with corticosteroid-resistant (CR) asthma and compare it with patients with corticosteroid-sensitive (CS) asthma and normal control subjects and explore whether bacteria in the airways of subjects with asthma may direct alterations in cellular responses to corticosteroids. Methods: 16S rRNA gene sequencing was performed on bronchoalveolar lavage (BAL) samples of 39 subjects with asthma and 12 healthy control subjects. In subjects with asthma, corticosteroid responsiveness was characterized, BAL macrophages were stimulated with pathogenic versus commensal microorganisms, and analyzed by real-time polymerase chain reaction for the expression of corticosteroid-regulated genes and cellular p38 mitogen-activated protein kinase (MAPK) activation. Measurements and Main Results: Of the 39 subjects with asthma, 29 were CR and 10 were CS. BAL microbiome from subjects with CR and CS asthma did not differ in richness, evenness, diversity, and community composition at the phylum level, but did differ at the genus level, with distinct genus expansions in 14 subjects with CR asthma. Preincubation of asthmatic airway macrophages with Haemophilus parainfluenzae, a uniquely expanded potential pathogen found only in CR asthma airways, resulted in p38 MAPK activation, increased IL-8 (P < 0.01), mitogen-activated kinase phosphatase 1 mRNA (P < 0.01) expression, and inhibition of corticosteroid responses (P < 0.05). This was not observed after exposure to commensal bacterium Prevotella melaninogenica. Inhibition of transforming growth factor-β–associated kinase-1 (TAK1), upstream activator of MAPK, but not p38 MAPK restored cellular sensitivity to corticosteroids. Conclusions: A subset of subjects with CR asthma demonstrates airway expansion of specific gram-negative bacteria, which trigger TAK1/MAPK activation and induce corticosteroid resistance. TAK1 inhibition restored cellular sensitivity to corticosteroids.